UBS analyst Danielle Antalffy reiterated a Buy rating and $154.00 price target on Abbott Labs (NYSE: ABT).

The analyst commented, "To us, the most meaningful takeaway from ABT’s 3Q25 earnings is the sustainability of double-digit MedTech sales growth, which we expect to continue. With shares under pressure today, and what we see is potential upside to 2026 Street estimates that ABT management 'blessed' today, we do see this as a buying opportunity. We’d be remiss if we didn’t acknowledge the ex-MedTech weakness which — coupled with long positioning into the quarter on expectations of a strong beat and raise — did disappoint. But, with: 1) Diagnostics comps easing as we enter 2026 along with China exposure increasingly immaterial to growth; and 2) U.S. Pediatric Nutrition likely to return to low-single-digit market growth following a lost WIC contract (to be more than offset by two new WICs won that will go into effect in 1H26), we think a return to stability in ex. MedTech businesses coupled with sustainable double-digit MedTech growth should put ABT on a path to consistent sales and EPS beats in 2026 and beyond."

For an analyst ratings summary and ratings history on Abbott Labs click here. For more ratings news on Abbott Labs click here.

Shares of Abbott Labs closed at $129.45 yesterday.